DE69809785D1 - Verwendung eines retinoidids zur in vivo erhöhung der entkopplung des ucp2 proteins - Google Patents

Verwendung eines retinoidids zur in vivo erhöhung der entkopplung des ucp2 proteins

Info

Publication number
DE69809785D1
DE69809785D1 DE69809785T DE69809785T DE69809785D1 DE 69809785 D1 DE69809785 D1 DE 69809785D1 DE 69809785 T DE69809785 T DE 69809785T DE 69809785 T DE69809785 T DE 69809785T DE 69809785 D1 DE69809785 D1 DE 69809785D1
Authority
DE
Germany
Prior art keywords
decoupling
retinoidide
uncovering
activity
vivo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69809785T
Other languages
English (en)
Other versions
DE69809785T2 (de
Inventor
Frederic Bouillaud
Daniel Ricquier
Zueco Eduardo Rial
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Cientificas CSIC
Centre National de la Recherche Scientifique CNRS
Original Assignee
Consejo Superior de Investigaciones Cientificas CSIC
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior de Investigaciones Cientificas CSIC, Centre National de la Recherche Scientifique CNRS filed Critical Consejo Superior de Investigaciones Cientificas CSIC
Application granted granted Critical
Publication of DE69809785D1 publication Critical patent/DE69809785D1/de
Publication of DE69809785T2 publication Critical patent/DE69809785T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69809785T 1997-08-05 1998-08-05 Verwendung eines retinoidids zur in vivo erhöhung der entkopplung des ucp2 proteins Expired - Fee Related DE69809785T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9710009A FR2767058B1 (fr) 1997-08-05 1997-08-05 Utilisation d'un compose de type retinoide, notamment l'acide retinoique pour la preparation d' un medicament destine au traitement de l'obesite.
PCT/ES1998/000225 WO1999007358A1 (es) 1997-08-05 1998-08-05 Utilizacion de un compuesto de tipo retinoide para modular in vivo la actividad desacopladora de la proteina ucp2

Publications (2)

Publication Number Publication Date
DE69809785D1 true DE69809785D1 (de) 2003-01-09
DE69809785T2 DE69809785T2 (de) 2003-09-18

Family

ID=9510039

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69809785T Expired - Fee Related DE69809785T2 (de) 1997-08-05 1998-08-05 Verwendung eines retinoidids zur in vivo erhöhung der entkopplung des ucp2 proteins

Country Status (9)

Country Link
US (2) US20030229143A1 (de)
EP (1) EP1018338B1 (de)
AT (1) ATE228362T1 (de)
AU (1) AU8543098A (de)
CA (1) CA2299270A1 (de)
DE (1) DE69809785T2 (de)
ES (2) ES2189213T3 (de)
FR (1) FR2767058B1 (de)
WO (1) WO1999007358A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576906B1 (en) 1999-10-08 2003-06-10 Symyx Technologies, Inc. Method and apparatus for screening combinatorial libraries for semiconducting properties
WO2001035096A2 (en) * 1999-11-10 2001-05-17 Mitokor Diseases associated with altered mitochondrial function
US6365796B1 (en) * 2000-02-16 2002-04-02 Beth Israel Deaconess Medical Center Transgenic UCP2 knockout mouse and use thereof
AU2001251132A1 (en) * 2000-03-31 2001-10-15 University Technology Corporation Expression of uncoupling protein (ucp) in plants
US7105718B2 (en) 2000-03-31 2006-09-12 The Regents Of The University Of Colorado Compositions and methods for regulating metabolism in plants
ES2177404B1 (es) * 2000-07-07 2004-09-16 Consejo Superior De Investigaciones Cientificas Procedimiento para la determinacion de la actividad de las proteinas desacoplantes (ucps) mediante la monitorizacion del consumo de nad (p) h.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5051449A (en) * 1991-02-27 1991-09-24 Kligman Albert M Treatment of cellulite with retinoids
US5219888A (en) * 1992-03-31 1993-06-15 American Cyanamid Company Use of retinoids for the treatment of coronary artery disease
TW272187B (de) * 1992-05-20 1996-03-11 Hoffmann La Roche
US5457129A (en) * 1993-05-17 1995-10-10 Research Development Foundation Inhibition of nitric oxide production by retinoic acid
WO1995018533A1 (en) * 1994-01-04 1995-07-13 The Trustees Of The University Of Pennsylvania Methods and compounds affecting adipocyte differentiation and obesity
FR2723315B1 (fr) * 1994-08-02 1996-10-25 Cird Galderma Procede et composition pour stimuler la differenciation des cellules preadipocytaires et traitements therapeutiques associes
US5489611A (en) * 1995-02-10 1996-02-06 Warner-Lambert Company Method for lowering plasma levels of lipoprotein (a)
FR2735367B1 (fr) * 1995-06-19 1997-07-18 Cird Galderma Utilisation de ligands specifiques des recepteurs rxrs
DE69631541T2 (de) * 1995-09-18 2004-12-23 Ligand Pharmaceuticals, Inc., San Diego Behandlung von NIDDM (nicht-insulinabhängigem Diabetes Mellitus)

Also Published As

Publication number Publication date
WO1999007358A1 (es) 1999-02-18
DE69809785T2 (de) 2003-09-18
FR2767058A1 (fr) 1999-02-12
FR2767058B1 (fr) 2000-05-05
AU8543098A (en) 1999-03-01
ES2189213T3 (es) 2003-07-01
EP1018338B1 (de) 2002-11-27
ATE228362T1 (de) 2002-12-15
ES2147519A1 (es) 2000-09-01
CA2299270A1 (en) 1999-02-18
ES2147519B1 (es) 2001-03-16
US20070015830A1 (en) 2007-01-18
US20030229143A1 (en) 2003-12-11
EP1018338A1 (de) 2000-07-12

Similar Documents

Publication Publication Date Title
ATE262336T1 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa- 4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14- dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
HUP0102612A2 (hu) Fehérje-tirozinfoszfatázokat moduláló vegyületek és ezeket tartalmazó gyógyászati készítmények
DK1521831T3 (da) Transgent dyr der udtrykker trunkeret alzheimers tauprotein
NZ263344A (en) Human bactericidal/permeability increasing (bpi) protein functional domain peptides and their use
DE69626539D1 (de) topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen
ATE466106T1 (de) Zusammensetzungen für die diagnose und therapie von erkrankungen, die im zusammenhang mit einer anomalen expression von futrinen (r-spondinen) stehen
LU93259I2 (fr) LETIFEND (Protein Q)
EA199700380A1 (ru) Бициклические ароматические соединения, фармацевтическая и косметическая композиции на их основе и применение косметической композиции
PT87523A (pt) Mischkristalle aus insulin und insulinderivaten verfahren zur herstellung dieser mischkristalle diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
EP1978362A3 (de) Cross-Beta-Struktur mit Amyloid-bindenden Proteinen und Verfahren für den Nachweis einer Cross-Beta-Struktur, zur Modulation der Fibrillenbildung von Cross-Beta-Strukturen und Cross-Beta-Struktur-vermittelter Toxizität
ATE82127T1 (de) N-acetylglucosamin-zubereitungen zur buccalen anwendung.
EA199700381A1 (ru) Диароматические соединения пропинила или диенила, промежуточные соединения, фармацевтические и косметические композиции на основе указанных соединений и применение косметических композиций
DE69809785T2 (de) Verwendung eines retinoidids zur in vivo erhöhung der entkopplung des ucp2 proteins
AU2001280812A1 (en) Gsk3 polypeptides
DE50212280D1 (de) Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
ATE322906T1 (de) Verwendung von langem pentraxin ptx3 zur behanlung von durch geänderte aktivität des fgf-2 wachstumsfaktors hervorgerufene krankheiten
DE69626522T2 (de) Peptide mit pronociceptiveigenschaften
DE60107888D1 (de) Beta-Interferon zur Behandlung von Immunerkrankungen
PT816504E (pt) Acetil-hidrolase para o factor activador das plaquetas, e seu gene
ATE317021T1 (de) Antisense modulierung von lfa-3
DE58906606D1 (de) Optisch aktive Rhodiumkomplexe von 3,4-Bis(diarylphosphino)-pyrrolidinen und ihre Verwendung zur Herstellung von Phosphinothricin durch asymmetrische Hydrierung.
DE59409413D1 (de) Verwendung von n,s-diacetylcystein-ethylester (dacee) zur herstellung eines medikaments zur behandlung viraler erkrankungen
DE69712182T2 (de) Peptide und ihre verwendung in der therapie von krankheiten des zöliakie-formenkreises
BR0308978A (pt) fragmentos de peptìdeos sintéticos ativos
DE69905489D1 (de) Protein c zur behandlung von sichelzellanämie und thalassämie

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee